Cargando…

Long-term safety and efficacy of ferric citrate in phosphate-lowering and iron-repletion effects among patients with on hemodialysis: A multicenter, open-label, Phase IV trial

BACKGROUND: We explored the long-term safety and efficacy of ferric citrate in hemodialysis patients in Taiwan, and further evaluated the iron repletion effect and change of iron parameters by different baseline groups. METHODS: This was a 12-month, Phase IV, multicenter, open-label study. The initi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Chien-Te, Lee, Chin-Chan, Wu, Ming-Ju, Chiu, Yi-Wen, Leu, Jyh-Gang, Wu, Ming-Shiou, Peng, Yu-Sen, Wu, Mai-Szu, Tarng, Der-Cherng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893642/ https://www.ncbi.nlm.nih.gov/pubmed/35239732 http://dx.doi.org/10.1371/journal.pone.0264727

Ejemplares similares

Safety and efficacy of ferric citrate in phosphate reduction and iron supplementation in patients with chronic kidney disease
por: Wu, Mei-Yi, et al.
Publicado: (2017)

Intravenous Ferric Chloride Hexahydrate Supplementation Induced Endothelial Dysfunction and Increased Cardiovascular Risk among Hemodialysis Patients
por: Kuo, Ko-Lin, et al.
Publicado: (2012)

Comparative Gut Microbiome Differences between Ferric Citrate and Calcium Carbonate Phosphate Binders in Patients with End-Stage Kidney Disease
por: Wu, Ping-Hsun, et al.
Publicado: (2020)

Calcium Repletion and Regional Citrate Anticoagulation in Hemodialysis and Hemodiafiltration: Using Dialysate Calcium to Modify Hypocalcemia
por: Dorie, Justin R., et al.
Publicado: (2021)

Correction: Intravenous Ferric Chloride Hexahydrate Supplementation Induced Endothelial Dysfunction and Increased Cardiovascular Risk among Hemodialysis Patients
por: Kuo, Ko-Lin, et al.
Publicado: (2013)

Ferric Citrate Hydrate as a Phosphate Binder and Risk of Aluminum Toxicity
por: Gupta, Ajay
Publicado: (2014)

Antiviral effects of ferric ammonium citrate
por: Wang, Hongbin, et al.
Publicado: (2018)

Physicochemical characterization of ferric pyrophosphate citrate
por: Gupta, Ajay, et al.
Publicado: (2018)

Ferric pyrophosphate citrate: interactions with transferrin
por: Pratt, Raymond, et al.
Publicado: (2018)

Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose—the randomized controlled HOMe aFers study
por: Emrich, I. E., et al.
Publicado: (2020)

Pharmacokinetics of ferric pyrophosphate citrate administered via dialysate and intravenously to pediatric patients on chronic hemodialysis
por: Pratt, Raymond D., et al.
Publicado: (2018)

Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients
por: Fishbane, Steven N., et al.
Publicado: (2015)

Factors associated with serum fetuin-A concentrations after long-term use of different phosphate binders in hemodialysis patients
por: Lin, Hsin-Hung, et al.
Publicado: (2016)

Mechanism of Action and Clinical Attributes of Auryxia(®) (Ferric Citrate)
por: Ganz, Tomas, et al.
Publicado: (2019)

Hemodialysis vascular access care during the COVID-19 pandemic
por: Yang, Chih-Yu, et al.
Publicado: (2020)

A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial
por: Hanudel, Mark R., et al.
Publicado: (2022)

Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients
por: Gupta, Ajay, et al.
Publicado: (2015)

Pharmacokinetics and Safety of Ferric Pyrophosphate Citrate in Chinese Subjects with and without Hemodialysis-Dependent Stage 5 Chronic Kidney Disease
por: Gan, Liangying, et al.
Publicado: (2022)

Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide
por: Nakayama, Masaaki, et al.
Publicado: (2017)

Individualized anemia management enhanced by ferric pyrophosphate citrate protocol
por: Chait, Yossi, et al.
Publicado: (2022)

Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients
por: Minakuchi, Hitoshi, et al.
Publicado: (2020)

Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model
por: Brunelli, Steven M., et al.
Publicado: (2017)

Ammonium Ferric Citrate induced Ferroptosis in Non-Small-Cell Lung Carcinoma through the inhibition of GPX4-GSS/GSR-GGT axis activity
por: Wu, Wei, et al.
Publicado: (2021)

Reduction of costs for anemia-management drugs associated with the use of ferric citrate
por: Thomas, Anila, et al.
Publicado: (2014)

Ferric citrate controls serum phosphorus in dialysis patients: retrospective data
por: Hain, Debra J., et al.
Publicado: (2017)

Ferric citrate is a safe and digestible source of iron in broilers and piglets
por: Männer, Klaus, et al.
Publicado: (2021)

Ferric Citrate Uptake Is a Virulence Factor in Uropathogenic Escherichia coli
por: Frick-Cheng, Arwen E., et al.
Publicado: (2022)

Ferric citrate and apo-transferrin enable erythroblast maturation with β-globin from hemogenic endothelium
por: Jeon, Soo-Been, et al.
Publicado: (2023)

Aldosterone and Mortality in Hemodialysis Patients: Role of Volume Overload
por: Hung, Szu-Chun, et al.
Publicado: (2013)

Factors affecting arteriovenous access patency after percutaneous transluminal angioplasty in chronic haemodialysis patients under vascular access monitoring and surveillance: a single-centre observational study
por: Wu, Chung-Kuan, et al.
Publicado: (2022)

Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data
por: Rodby, Roger A., et al.
Publicado: (2015)

Comment on: “Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Mode”
por: Rascati, Karen
Publicado: (2017)

Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease
por: Chertow, Glenn M., et al.
Publicado: (2017)

Renoprotective effects of ferric citrate in a mouse model of chronic kidney disease
por: Hanudel, Mark R., et al.
Publicado: (2022)

Pharmacokinetics and Safety of Intravenous Ferric Pyrophosphate Citrate: Equivalence to Administration via Dialysate
por: Marbury, Thomas, et al.
Publicado: (2022)

Association of vascular access flow with short-term and long-term mortality in chronic haemodialysis patients: a retrospective cohort study
por: Wu, Chung-Kuan, et al.
Publicado: (2017)

Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses
por: Block, Geoffrey A, et al.
Publicado: (2019)

Ferric Ammonium Citrate Upregulates PD-L1 Expression through Generation of Reactive Oxygen Species
por: Choi, Eun Jung, et al.
Publicado: (2022)

Comparison of Simplified Creatinine Index and Systemic Inflammatory Markers for Nutritional Evaluation of Hemodialysis Patients
por: Tsai, Ming-Tsun, et al.
Publicado: (2021)

Ferric citrate and ferric EDTA but not ferrous sulfate drive amphiregulin-mediated activation of the MAP kinase ERK in gut epithelial cancer cells
por: Scheers, Nathalie M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kr4fsi7h5qore2409v2sirp9f8